Study guide
20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome
MRCP UK
Track your progress as you read
Finished sections get a check mark.
1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy
1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique
2 Clinical Sciences: Cellular, Genetic & Molecular Medicine
2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders
3 Clinical Sciences: Anatomy, Physiology & Immunology
3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions
4 Clinical Sciences: Statistics, Epidemiology & Trial Design
4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification
5 Clinical Pharmacology, Therapeutics & Toxicology
5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols
6 Cardiology: Coronary Artery Disease & Heart Failure
6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation
7 Cardiology: Arrhythmias, Valvular & Pericardial Disease
7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases
8 Respiratory Medicine: Airway & Parenchymal Lung Disease
8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis
9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders
9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing
10 Gastroenterology: Luminal Gastrointestinal Disease
10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia
11 Gastroenterology: Liver, Biliary & Pancreatic Disease
11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis
12 Endocrinology & Diabetes: Diabetes & Thyroid
12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules
13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium
13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease
14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease
14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases
15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance
15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis
16 Neurology: Cerebrovascular, Headache & Demyelinating Disease
16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases
17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease
17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders
18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease
18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies
19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy
19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease
20 Infectious Diseases & Tropical Medicine
20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites
21 Haematology: Anaemias & Red Cell Disorders
21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease
22 Haematology: Malignancy, Coagulation & Transfusion Medicine
22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions
23 Psychiatry in General Medicine
23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law
24 Geriatric Medicine
24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers
25 Dermatology
25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy
26 Oncology & Palliative Medicine
26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control
27 Medical Ophthalmology
27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease
20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome
Key Takeaways Explain This Topic AI
Bacterial meningitis CSF shows neutrophilic pleocytosis, high protein and a CSF:plasma glucose ratio below 0.4; tuberculous meningitis shows lymphocytes with very high protein and very low glucose.
Dexamethasone is given with or just before the first antibiotic dose in suspected pneumococcal meningitis and improves neurological outcome.
Listeria monocytogenes meningitis requires amoxicillin, which is added for patients over 60 years, pregnant women and the immunosuppressed because cephalosporins do not cover it.
Last updated: September 2026
3. Acute Bacterial Meningitis: Pathogens, Presentation & Emergency Management
Acute bacterial meningitis is a medical emergency with high mortality ( 15 – 25 % 15\text{–}25\% 15 – 25% ) and substantial risk of long-term neurological sequelae (sensorineural hearing loss, focal cognitive deficits, epilepsy). Rapid parenchymal and meningeal inflammation results from subarachnoid bacterial replication following haematogenous seeding or direct contiguous spread (e.g., otitis media, mastoiditis, sinus fracture).
Causative Pathogens Stratified by Host Age and Risk
Immunocompetent Adults (Ages 18–60):
Streptococcus pneumoniae (Pneumococcus): The most common causative pathogen overall in adults ( > 50 % > 50\% > 50% of cases). Associated with severe disease, impaired consciousness, focal neurological deficits, and high mortality. Predisposing factors include asplenia, otitis media, pneumonia, head injury with basilar skull fracture and CSF leak, and alcohol excess.
Neisseria meningitidis (Meningococcus): Predominates in adolescents and young adults (ages 15–24, university halls, military barracks). Serogroups B, C, W, and Y are principal culprits in the UK. Characterized by rapid progression and petechial or non-blanching purpuric skin rash.
Neonates ( < 3 months < 3\text{ months} < 3 months ): Streptococcus agalactiae (Group B Streptococcus), Escherichia coli (K1 capsular strain), and Listeria monocytogenes .
Elderly Adults ( > 60 years > 60\text{ years} > 60 years ) & Immunocompromised Hosts:
Listeria monocytogenes : A facultative intracellular Gram-positive bacillus acquired via ingestion of unpasteurized dairy, soft cheeses, or deli meats. Causes severe rhombencephalitis (brainstem encephalitis), ataxia, and cranial neuropathies. Predominantly strikes individuals aged > 60 > 60 > 60 , pregnant women, and patients with impaired cell-mediated immunity (haematological malignancy, chemotherapy, biologic agents, corticosteroid therapy, cirrhosis, and alcohol misuse).
Clinical Presentation
The Classic Triad: Fever, altered mental state (GCS < 15 < 15 < 15 ), and neck stiffness (meningism) . All three features are present in only 45 % 45\% 45% of patients, but > 95 % > 95\% > 95% possess at least two signs from headache, fever, neck stiffness, and altered consciousness.
Physical Signs of Meningeal Irritation:
Kernig's Sign: Inability to extend the knee beyond 135 ∘ 135^\circ 13 5 ∘ when the hip is flexed at 90 ∘ 90^\circ 9 0 ∘ due to severe pain and hamstring spasm.
Brudzinski's Sign: Involuntary flexion of the hips and knees upon passive flexion of the patient's neck.
Cutaneous Hallmarks: Non-blanching petechial or purpuric rash is pathognomonic of meningococcal septicaemia ( N. meningitidis ), although widespread purpura fulminans can rarely complicate overwhelming pneumococcal sepsis in asplenic patients.
Emergency Management Protocol (BIA & NICE Guidelines)
Immediate Parenteral Antibiotic Administration: Antibiotics must never be delayed for neuroimaging or lumbar puncture. If bacterial meningitis is suspected in primary care, immediate intramuscular or intravenous benzylpenicillin (or ceftriaxone) should be administered prior to urgent hospital transfer.
Hospital Empirical Antimicrobial Regimen:
Adults aged 18–60 years: Intravenous ceftriaxone 2 g 2\text{ g} 2 g 12-hourly (or cefotaxime 2 g 2\text{ g} 2 g 6-hourly). High-dose third-generation cephalosporins achieve bactericidal subarachnoid concentrations against penicillin-resistant pneumococci and meningococci.
Adults aged > 60 > 60 > 60 years OR immunocompromised OR pregnant: Add intravenous ampicillin or amoxicillin 2 g 2\text{ g} 2 g 4-hourly to provide dedicated coverage against Listeria monocytogenes (which is intrinsically resistant to all cephalosporins).
Severe Penicillin/Beta-lactam Anaphylaxis: IV chloramphenicol ( 25 mg/kg 25\text{ mg/kg} 25 mg/kg 6-hourly) plus IV vancomycin, plus co-trimoxazole if Listeria coverage is required.
Adjunctive Corticosteroid Therapy (Dexamethasone):
Regimen: Intravenous dexamethasone 10 mg 10\text{ mg} 10 mg 6-hourly (or 0.15 mg/kg 0.15\text{ mg/kg} 0.15 mg/kg QDS).
Timing: Must be administered prior to or concurrently with the first dose of antimicrobial therapy (up to a maximum of 4 hours after antibiotics; ineffective if given > 12 > 12 > 12 hours later).
Evidence & Duration: The European Dexamethasone in Adulthood Bacterial Meningitis trial demonstrated that adjunctive dexamethasone significantly reduces unfavourable outcomes (relative risk 0.59) and mortality in Streptococcus pneumoniae meningitis, and significantly reduces sensorineural deafness in meningococcal disease. Continue for 4 days if S. pneumoniae is confirmed; discontinue immediately if Listeria or non-bacterial aetiologies are identified.
Indications for Cranial CT Scan Prior to Lumbar Puncture
Performing a lumbar puncture in the presence of an intracranial space-occupying lesion or acute brain swelling risks fatal transtentorial or cerebellar tonsillar herniation (coning) . CT brain is mandatory before LP if any of the following 'red flag' criteria are present:
- Focal neurological deficits (e.g., hemiparesis, visual field defect, unequal pupils, facial asymmetry)
- New-onset or recent seizures (within preceding 1 week)
Significant encephalopathy or depressed consciousness ( GCS < 12 < 12 < 12 or a rapid fall in GCS ≥ 2 \ge 2 ≥ 2 points)
- Papilloedema on fundoscopy (indicates established raised intracranial pressure)
- Severe immunocompromised state (known HIV/AIDS, immunosuppressive therapy, active organ transplant)
Note: If CT is indicated, obtain blood cultures, immediately administer IV dexamethasone and empirical antibiotics, and arrange CT imaging without delaying therapeutic intervention.
Chemoprophylaxis for Close Contacts
Close household contacts, dormitory room-mates, and kissing contacts of confirmed meningococcal disease ( N. meningitidis ) within the 7 days prior to onset require urgent chemoprophylaxis to eradicate nasopharyngeal carriage:
First-line UKHSA/NICE Regimen: A single oral dose of ciprofloxacin 500 mg 500\text{ mg} 500 mg (safe across all ages and during pregnancy under UKHSA guidance).
Alternative Regimen: Oral rifampicin 600 mg 600\text{ mg} 600 mg 12-hourly for 2 days (renders oral contraceptives ineffective; stains urine/soft contact lenses red-orange).
Pregnancy Alternative: Intramuscular ceftriaxone 250 mg 250\text{ mg} 250 mg stat .
Note: Close contacts of pneumococcal or Listeria meningitis do not require chemoprophylaxis.
4. Cerebrospinal Fluid (CSF) Analysis in CNS Infections
Interpretation of lumbar puncture parameters is a recurring cornerstone of MRCP(UK) Part 1 examinations.
Parameter Normal Range Acute Bacterial Meningitis Viral (Aseptic) Meningitis Tuberculous (TB) Meningitis Fungal ( Cryptococcal ) Meningitis
Opening Pressure 10 – 20 cmH 2 O 10\text{–}20\text{ cmH}_2\text{O} 10 – 20 cmH 2 O Elevated ( > 25 – 30 cmH 2 O > 25\text{–}30\text{ cmH}_2\text{O} > 25 – 30 cmH 2 O ) Normal or mildly elevated ( 15 – 25 cmH 2 O 15\text{–}25\text{ cmH}_2\text{O} 15 – 25 cmH 2 O ) Markedly elevated ( > 30 cmH 2 O > 30\text{ cmH}_2\text{O} > 30 cmH 2 O ) Severely elevated ( > 30 – 40 cmH 2 O > 30\text{–}40\text{ cmH}_2\text{O} > 30 – 40 cmH 2 O )
Macroscopic Appearance Clear, colourless Turbid, cloudy, or purulent Clear or slightly opalescent Clear or opalescent; fibrin web / cobweb clot on standing Clear or opalescent
White Blood Cell Count < 5 cells/ μ L < 5\text{ cells/}\mu\text{L} < 5 cells/ μ L Marked pleocytosis ( 1 , 000 – 10 , 000 + / μ L 1,000\text{–}10,000+\text{/}\mu\text{L} 1 , 000 – 10 , 000 + / μ L ) Mild-to-moderate ( 50 – 500 / μ L 50\text{–}500\text{/}\mu\text{L} 50 – 500 / μ L ) Moderate ( 100 – 500 / μ L 100\text{–}500\text{/}\mu\text{L} 100 – 500 / μ L ) Mild-to-moderate ( 20 – 500 / μ L 20\text{–}500\text{/}\mu\text{L} 20 – 500 / μ L )
Dominant Cell Type Lymphocytes / Monocytes Polymorphonuclear neutrophils ( > 80 – 90 % > 80\text{–}90\% > 80 – 90% ) Mononuclear lymphocytes ( > 90 % > 90\% > 90% ) Mononuclear lymphocytes ( > 80 % > 80\% > 80% ) Mononuclear lymphocytes ( > 80 % > 80\% > 80% )
CSF Protein 0.15 – 0.45 g/L 0.15\text{–}0.45\text{ g/L} 0.15 – 0.45 g/L Markedly elevated ( > 1.0 – 5.0 g/L > 1.0\text{–}5.0\text{ g/L} > 1.0 – 5.0 g/L ) Normal or mildly elevated ( 0.45 – 1.0 g/L 0.45\text{–}1.0\text{ g/L} 0.45 – 1.0 g/L ) Extremely high ( 1.5 – 6.0 + g/L 1.5\text{–}6.0+\text{ g/L} 1.5 – 6.0 + g/L ) due to basal exudates Elevated ( 0.5 – 2.5 g/L 0.5\text{–}2.5\text{ g/L} 0.5 – 2.5 g/L )
CSF:Serum Glucose Ratio > 0.60 > 0.60 > 0.60 ( > 60 % > 60\% > 60% ) Markedly reduced ( < 0.40 < 0.40 < 0.40 or undetectable) Normal ( > 0.60 > 0.60 > 0.60 ) Extremely low ( < 0.30 < 0.30 < 0.30 ) Low-to-normal ( < 0.40 – 0.50 < 0.40\text{–}0.50 < 0.40 – 0.50 )
Special Diagnostic Tests Sterile Gram stain ( 60 – 80 % 60\text{–}80\% 60 – 80% positive), PCR, bacterial culture Multiplex viral PCR (HSV-1, HSV-2, VZV, enteroviruses) Acid-fast bacilli (AFB) stain, GeneXpert MTB/RIF, liquid culture India ink preparation (encapsulated yeasts), Cryptococcal antigen (CrAg)
5. Toxic Shock Syndrome (TSS): Staphylococcal vs. Streptococcal
Toxic shock syndrome is an acute, life-threatening toxin-mediated multisystem illness characterized by rapid onset of fever, hypotension, generalized erythroderma, and progressive multiorgan failure.
Molecular Pathophysiology: The Superantigen Mechanism
Conventional peptide antigens require internalisation, lysosomal processing by antigen-presenting cells (APCs), and presentation within the peptide-binding groove of Major Histocompatibility Complex (MHC) Class II molecules to activate specific T-cell receptor (TCR) clones ( < 0.01 % < 0.01\% < 0.01% of total T-cell pool).
In contrast, bacterial superantigens circumvent normal processing. They bind directly and simultaneously to the external invariant surface of MHC Class II molecules on APCs and specific Variable beta ( V β V_\beta V β ) regions of T-cell receptors. This bypasses antigen specificity and triggers massive, uncontrolled polyclonal T-cell activation ( 5 – 20 % 5\text{–}20\% 5 – 20% of all systemic T-lymphocytes) . The ensuing hypercytokinaemia (interferon-gamma, IL-1, IL-2, IL-6, TNF- α \alpha α , and TNF- β \beta β ) induces diffuse capillary leak, distributive vasoplegia, and multiorgan destruction.
Staphylococcal vs. Streptococcal Toxic Shock Syndrome
- Clinical Characteristic Staphylococcal TSS Streptococcal TSS
- Primary Causative Organism Staphylococcus aureus Streptococcus pyogenes (Group A Streptococcus [GAS])
Culprit Exotoxins Toxic Shock Syndrome Toxin-1 (TSST-1) ( 75 % 75\% 75% ), Enterotoxins B and C Streptococcal Pyrogenic Exotoxins A, B, and C (SpeA, SpeB, SpeC)
Clinical Predisposition High-absorbency tampon use, retained vaginal packs, nasal packing post-rhinoplasty, surgical wound haematomas, burns Soft-tissue infections ( necrotizing fasciitis , cellulitis), influenza infection, deep surgical site infections
Blood Culture Positivity Rarely positive ( < 5 % < 5\% < 5% ) (toxin-mediated disease from localised colonisation) Frequently positive ( > 50 – 60 % > 50\text{–}60\% > 50 – 60% ) (high incidence of concurrent invasive bacteraemia)
- Soft Tissue Necrosis Absent Common, extensive tissue destruction and severe localized pain
- Mortality Rate 3 – 5 % 3\text{–}5\% 3 – 5% 30 – 50 % 30\text{–}50\% 30 – 50%
- Diagnostic Hallmarks & Multiorgan Criteria (CDC/UK Standards)
- Fever: Temperature ≥ 38.9 ∘ C \ge 38.9^\circ\text{C} ≥ 38. 9 ∘ C ( 102 ∘ F 102^\circ\text{F} 10 2 ∘ F )
- Hypotension: Systolic blood pressure ≤ 90 mmHg \le 90\text{ mmHg} ≤ 90 mmHg or orthostatic syncope
- Diffuse Rash: Generalized macular erythroderma resembling a severe sunburn
Desquamation: Fine lamellar desquamation occurring characteristically 1 to 2 weeks following disease onset , particularly involving the palms of the hands and soles of the feet
Multisystem Involvement ( ≥ 3 \ge 3 ≥ 3 organ systems):
- Gastrointestinal: Profuse vomiting or watery diarrhoea at onset
- Muscular: Severe myalgia or serum creatine kinase (CK) elevated ≥ 2 × \ge 2\times ≥ 2 × upper limit of normal
- Mucous membranes: Intense erythema of vaginal, oropharyngeal, or conjunctival mucosa without purulence
Renal: Serum creatinine ≥ 2 × \ge 2\times ≥ 2 × upper limit of normal or pyuria ( > 5 > 5 > 5 WBCs/HPF) without infection
- Hepatic: Total bilirubin, ALT, or AST ≥ 2 × \ge 2\times ≥ 2 × upper limit of normal
- Haematological: Severe thrombocytopenia ( < 100 × 10 9 /L < 100 \times 10^9\text{/L} < 100 × 1 0 9 /L )
- Central Nervous System: Disorientation, delirium, or altered consciousness without focal signs
- Therapeutic Management
Antitoxin Pharmacotherapy: Intravenous clindamycin ( 600 – 900 mg 600\text{–}900\text{ mg} 600 – 900 mg 6- to 8-hourly) is mandatory. As a lincosamide that binds the 50S ribosomal subunit, clindamycin directly inhibits bacterial protein synthesis , halting the transcription and transcription-independent release of superantigen exotoxins (TSST-1, SpeA). This action is unaffected by the 'Eagle effect' (reduced penicillin efficacy in high bacterial inocula during stationary growth phase).
Bactericidal Backbone: Combine clindamycin with high-dose intravenous flucloxacillin (or vancomycin if methicillin-resistant S. aureus [MRSA] is suspected) for Staphylococcal TSS, or intravenous benzylpenicillin (or ceftriaxone) for Streptococcal TSS.
Intravenous Immunoglobulin (IVIG): High-dose IVIG ( 1 – 2 g/kg 1\text{–}2\text{ g/kg} 1 – 2 g/kg ) contains high titres of neutralizing antibodies against superantigen exotoxins. Recommended in severe, refractory streptococcal TSS or necrotizing fasciitis.
Surgical Source Control: Immediate removal of retained foreign bodies (tampons, nasal tampons, surgical packs) and urgent radical surgical debridement of necrotic soft tissue in suspected necrotizing fasciitis.